title: Pharmacokinetic evaluation of etravirine.
abstract: BACKGROUND
  successful long-term treatment of HIV is hindered by development of resistance and providing active regimens for treatment-experienced patients remains challenging. Development of antiretrovirals active against resistant virus, such as the diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine, is important to broaden treatment options to patients who have few available.
  
  
  METHODS
  we summarise pharmacology, pharmacokinetics, drug-drug interactions and clinical data of etravirine based on a PubMed search between 01 January 2003 and 01 September 2010 as well as relevant information from conference proceedings and the latest Summary of Product Characteristics and US Prescribing Information.
  
  
  RESULTS
  the reader will gain a comprehensive overview of etravirine clinical pharmacology, drug-drug interactions and mechanism of action. Information regarding efficacy, safety and tolerability in specific patients groups is provided to allow the reader to form an opinion regarding the role of etravirine in clinical practice.
  
  
  CONCLUSIONS
  etravirine, along with other new antiretrovirals, has widened treatment options for patients with multi-drug resistance. Etravirine is well tolerated with the majority of drug-drug interactions manageable and is effective in triple-class experienced patients. Clinical studies investigating etravirine in treatment-naive patients are ongoing to further clarify its safety and resistance profile.
authors.affiliation: Royal Liverpool & Broadgreen University Hospital Trust, NIHR Biomedical Research Centre, Liverpool, UK. laurad@liv.ac.uk
authors.forename: Laura
authors.initials: L
authors.lastname: Dickinson
authors.forename: Saye
authors.initials: S
authors.lastname: Khoo
authors.forename: David
authors.initials: D
authors.lastname: Back
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009570:Nitriles; D011724:Pyridazines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology
chemical_list: D019380:Anti-HIV Agents; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine